Supplementary Figure 2 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Oukseub Lee,Megan E. Sullivan,Yanfei Xu,Chiara Rogers,Miguel Muzzio,Irene Helenowski,Ali Shidfar,Zexian Zeng,Hari Singhal,Borko Jovanovic,Nora Hansen,Kevin P. Bethke,Peter H. Gann,William Gradishar,J. Julie Kim,Susan E. Clare,Seema A. Khan

crossref（2023）

引用 0|浏览17

暂无评分

摘要

Supplemental Figure 2. Ki67 Change relative to treatment duration. There was no significant correlation between change in Ki67 and treatment duration, in either TPA or placebo arms.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要